 | • レポートコード：MRC2209B009 • 出版社/出版日：Persistence Market Research / 2022年7月12日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、世界のバイオシミラー・インスリン市場について調査し、エグゼクティブサマリー、市場概要、主要市場トレンド、主要成功要因、市場背景、新型コロナウイルス感染症の危機分析、需要分析・予測、価格分析、製品別（インスリングラルギン、インスリンアナログ、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法、以下の構成でまとめております。本書では、Biocon、Eli Lilly and Company、Sanofi、BGP Pharma、Aspen、Mylan（Viatris）などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場トレンド ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・需要分析・予測 ・価格分析 ・世界のバイオシミラー・インスリン市場規模：製品別 - インスリングラルギンの市場規模 - インスリンアナログの市場規模 - その他製品の市場規模 ・世界のバイオシミラー・インスリン市場規模：流通チャネル別 - 病院薬局における市場規模 - 小売薬局における市場規模 - オンライン薬局における市場規模 ・世界のバイオシミラー・インスリン市場規模：地域別 - 北米のバイオシミラー・インスリン市場規模 - 中南米のバイオシミラー・インスリン市場規模 - ヨーロッパのバイオシミラー・インスリン市場規模 - アジア太平洋のバイオシミラー・インスリン市場規模 - 中東・アフリカのバイオシミラー・インスリン市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Biosimilar insulin Market: Scope of Report
The latest publication by Persistence Market Research on the global biosimilar insulin market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for biosimilar insulin market products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the biosimilar insulin market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the biosimilar insulin market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the biosimilar insulin market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the biosimilar insulin market offers information divided into three important segments – product, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Insulin Glargine
Insulin Analog
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
APAC
MEA
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for biosimilar insulin over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the biosimilar insulin market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the biosimilar insulin market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the biosimilar insulin market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion And Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Key Products USP/Feature Analysis
4.2. Regulatory Scenario
4.3. Key Promotional Strategies By Manufacturers
4.4. Recent Product Launches
4.5. Value Chain Analysis
4.6. Product Adoption Analysis by Region
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Outlook
5.1.3. Parent Market Analysis (Insulin Market)
5.2. Forecast Factors – Relevance & Impact
5.2.1. Growing Prevalence Of Diabetes
5.2.2. Increasing Research and Development Activities
5.2.3. New Product Launches
5.2.4. Increasing Number Of Clinical Trials
5.2.5. Patent Expiry for Insulin
5.2.6. Growing Geriatric Population
5.2.7. Increasing Insulin Manufacturers
5.2.8. Requirement of Cost-Efficient Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. 2021 Market Scenario
6.2. COVID-19 and Impact Analysis
6.2.1. By Product
6.2.2. By Distribution Channel
6.2.3. By Region
7. Global Biosimilar Insulin Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Biosimilar Insulin Market – Pricing Analysis
8.1. Regional Pricing Analysis By Product
8.2. Global Average Pricing Analysis Benchmark
8.3. Pricing Break-up
8.3.1. Manufacturer Level Pricing
8.3.2. Distributor Level Pricing
8.4. Pricing Assumptions
9. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
9.3.1. Insulin Glargine
9.3.2. Insulin Analog
9.3.3. Others
9.4. Market Attractiveness Analysis By Product
10. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific (APAC)
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
12.4.1. By Country
12.4.1.1. U.S.
12.4.1.2. Canada
12.4.2. By Product
12.4.3. By Distribution Channel
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Product
12.5.3. By Distribution Channel
12.6. Key Market Participants – Intensity Mapping
12.7. Drivers and Restraints – Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Biosimilar Insulin Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product
12.8.1.2.2. By Distribution Channel
12.8.2. Canada Biosimilar Insulin Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product
12.8.2.2.2. By Distribution Channel
13. Latin America Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
13.4.1. By Country
13.4.1.1. Brazil
13.4.1.2. Argentina
13.4.1.3. Mexico
13.4.1.4. Rest of Latin America
13.4.2. By Product
13.4.3. By Distribution Channel
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product
13.5.3. By Distribution Channel
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Brazil Biosimilar Insulin Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Distribution Channel
13.8.2. Argentina Biosimilar Insulin Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Distribution Channel
13.8.3. Mexico Biosimilar Insulin Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product
13.8.3.2.2. By Distribution Channel
14. Europe Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. Germany
14.4.1.2. Italy
14.4.1.3. France
14.4.1.4. U.K.
14.4.1.5. Spain
14.4.1.6. BENELUX
14.4.1.7. Nordic Countries
14.4.1.8. Russia
14.4.1.9. Rest of Europe
14.4.2. By Product
14.4.3. By Distribution Channel
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product
14.5.3. By Distribution Channel
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Biosimilar Insulin Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Distribution Channel
14.8.2. France Biosimilar Insulin Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Distribution Channel
14.8.3. Italy Biosimilar Insulin Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Distribution Channel
14.8.4. Spain Biosimilar Insulin Market
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product
14.8.4.2.2. By Distribution Channel
14.8.5. U.K. Biosimilar Insulin Market
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Product
14.8.5.2.2. By Distribution Channel
14.8.6. BENULUX Biosimilar Insulin Market
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Product
14.8.6.2.2. By Distribution Channel
14.8.7. Nordic Countries Biosimilar Insulin Market
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Product
14.8.7.2.2. By Distribution Channel
14.8.8. Russia Biosimilar Insulin Market
14.8.8.1. Introduction
14.8.8.2. Market Analysis and Forecast by Market Taxonomy
14.8.8.2.1. By Product
14.8.8.2.2. By Distribution Channel
15. Asia Pacific (APAC) Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. China
15.4.1.2. Japan
15.4.1.3. India
15.4.1.4. Australia
15.4.1.5. New Zealand
15.4.2. By Product
15.4.3. By Distribution Channel
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product
15.5.3. By Distribution Channel
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Biosimilar Insulin Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Distribution Channel
15.8.2. Japan Biosimilar Insulin Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Distribution Channel
15.8.3. India Biosimilar Insulin Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Distribution Channel
15.8.4. Australia Biosimilar Insulin Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Distribution Channel
15.8.5. New Zealand Biosimilar Insulin Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Distribution Channel
16. Middle East and Africa (MEA) Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. GCC Countries
16.4.1.2. Israel
16.4.1.3. Turkey
16.4.1.4. Egypt
16.4.1.5. North Africa
16.4.1.6. South Africa
16.4.1.7. Rest of Middle East and Africa
16.4.2. By Product
16.4.3. By Distribution Channel
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product
16.5.3. By Distribution Channel
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. GCC Countries Biosimilar Insulin Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Distribution Channel
16.8.2. Israel Biosimilar Insulin Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Distribution Channel
16.8.3. Turkey Biosimilar Insulin Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Distribution Channel
16.8.4. Egypt Biosimilar Insulin Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Distribution Channel
16.8.5. North Africa Biosimilar Insulin Market
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Product
16.8.5.2.2. By Distribution Channel
16.8.6. South Africa Biosimilar Insulin Market
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Product
16.8.6.2.2. By Distribution Channel
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Share Analysis of Top Players
17.3. Market Presence Analysis
17.3.1. Regional footprint of Players
17.3.2. Platform Type foot print by Players
17.3.3. Channel Foot Print by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Biocon
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Key Financials
18.3.1.4. Geographical Footprint
18.3.1.5. SWOT Analysis
18.3.1.6. Key Developments
18.3.1.7. Strategy Overview
18.3.1.7.1. Channel Strategy
18.3.1.7.2. Marketing Strategy
18.3.1.7.3. Product Strategy
18.3.2. Eli Lilly and Company
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Key Financials
18.3.2.4. Geographical Footprint
18.3.2.5. SWOT Analysis
18.3.2.6. Key Developments
18.3.2.7. Strategy Overview
18.3.2.7.1. Channel Strategy
18.3.2.7.2. Marketing Strategy
18.3.2.7.3. Product Strategy
18.3.3. Sanofi
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Key Financials
18.3.3.4. Geographical Footprint
18.3.3.5. SWOT Analysis
18.3.3.6. Key Developments
18.3.3.7. Strategy Overview
18.3.3.7.1. Channel Strategy
18.3.3.7.2. Marketing Strategy
18.3.3.7.3. Product Strategy
18.3.4. BGP Pharma
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Key Financials
18.3.4.4. Geographical Footprint
18.3.4.5. SWOT Analysis
18.3.4.6. Key Developments
18.3.4.7. Strategy Overview
18.3.4.7.1. Channel Strategy
18.3.4.7.2. Marketing Strategy
18.3.4.7.3. Product Strategy
18.3.5. Aspen
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Key Financials
18.3.5.4. Geographical Footprint
18.3.5.5. SWOT Analysis
18.3.5.6. Key Developments
18.3.5.7. Strategy Overview
18.3.5.7.1. Channel Strategy
18.3.5.7.2. Marketing Strategy
18.3.5.7.3. Product Strategy
18.3.6. Mylan (Viatris)
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Key Financials
18.3.6.4. Geographical Footprint
18.3.6.5. SWOT Analysis
18.3.6.6. Key Developments
18.3.6.7. Strategy Overview
18.3.6.7.1. Channel Strategy
18.3.6.7.2. Marketing Strategy
18.3.6.7.3. Product Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Table 1: Global Biosimilar Insulin Market Value (US$ Mn) Forecast by Region, 2017 & 2032Table 2: Global Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 3: Global Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
Table 4: North America Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
Table 5: North America Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 6: North America Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
Table 7: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
Table 8: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 9: Latin America Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
Table 10: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
Table 11: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 12: Europe Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
Table 13: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
Table 14: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 15: Asia Pacific (APAC) Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032
Table 16: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast by Country, 2017 & 2032
Table 17: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast by Product, 2017 & 2032
Table 18: Middle East and Africa (MEA) Biosimilar Insulin Market Value (US$ Mn) Forecast By Distribution Channel, 2017 & 2032